TG Therapeutics, Inc.
(NASDAQ CM: TGTX)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of TG Therapeutics, Inc. ("TG" or the "Company") on behalf of stockholders. A class action complaint has been filed against TG. The complaint alleges that defendants made a series of misrepresentations concerning the safety and commercial prospects of the Company's two most important drugs, Ublituximab and Umbralisib. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain FDA approval of the Umbralisib MZL/FL New Drug Application ("NDA"), the U2 Biologics License Application ("BLA"), the U2 supplemental NDA, or the Ublituximab RMS BLA in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times.